Role of cardiac MRI in evaluating patients with Anderson-Fabry disease: Assessing cardiac effects of long-term enzyme replacement therapy (580 views)
Radiol Med (ISSN: 0033-8362, 1826-6983, 1826-6983electronic), 2012 Feb; 117(1): 19-28.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 1.461, 5-year impact factor: 1.44
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-84857659385&partnerID=40&md5=62d16e38ff417ed7d6980eee596c596a
Keywords: Anderson-Fabry Disease, Cardiac, Mri, T2 Relaxation Time, Agalsidase Beta, Alpha Galactosidase, Isoenzyme, Adult, Article, Enzyme Replacement, Female, Heart Disease, Human, Methodology, Nuclear Magnetic Resonance Imaging, Pathophysiology, Risk Factor, Vectorcardiography, Alpha-Galactosidase, Enzyme Replacement Therapy, Cine,
Affiliations:
*** IBB - CNR ***
Dipartimento di Scienze Biomorfologiche e Funzionali, Università Degli Studi 'Federico II', Via Posillipo 196, Napoli 80123, Italy
Dipartimento di Nefrologia, Università Degli Studi 'Federico II', Napoli, Italy
Dipartimento di Medicina Clinica e Scienze Cardiovascolari Ed Immunologiche, Università Degli Studi 'Federico II', Napoli, Italy
Istituto di Biostrutture e Bioimmagini, CNR, Napoli, Italy
Azienda Ospedaliera-Universitaria di Parma, Parma, Italy
References:
Not available.
Radiol Med (ISSN: 0033-8362, 1826-6983, 1826-6983electronic), 2012 Feb; 117(1): 19-28.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 1.461, 5-year impact factor: 1.44
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-84857659385&partnerID=40&md5=62d16e38ff417ed7d6980eee596c596a
Keywords: Anderson-Fabry Disease, Cardiac, Mri, T2 Relaxation Time, Agalsidase Beta, Alpha Galactosidase, Isoenzyme, Adult, Article, Enzyme Replacement, Female, Heart Disease, Human, Methodology, Nuclear Magnetic Resonance Imaging, Pathophysiology, Risk Factor, Vectorcardiography, Alpha-Galactosidase, Enzyme Replacement Therapy, Cine,
Affiliations:
*** IBB - CNR ***
Dipartimento di Scienze Biomorfologiche e Funzionali, Università Degli Studi 'Federico II', Via Posillipo 196, Napoli 80123, Italy
Dipartimento di Nefrologia, Università Degli Studi 'Federico II', Napoli, Italy
Dipartimento di Medicina Clinica e Scienze Cardiovascolari Ed Immunologiche, Università Degli Studi 'Federico II', Napoli, Italy
Istituto di Biostrutture e Bioimmagini, CNR, Napoli, Italy
Azienda Ospedaliera-Universitaria di Parma, Parma, Italy
References:
Not available.
Role of cardiac MRI in evaluating patients with Anderson-Fabry disease: Assessing cardiac effects of long-term enzyme replacement therapy
Purpose: Anderson-Fabry disease is a multisystemic disorder of lipid metabolism secondary to X-chromosome alterations and is frequently associated with cardiac manifestations such as left ventricular (LV) hypertrophy, gradually leading to an alteration in cardiac performance. The purpose of this study was to monitor, using magnetic resonance imaging (MRI), any changes produced by enzyme replacement therapy with agalsidase beta at the cardiac level in patients with Anderson-Fabry disease. Materials and methods: Sixteen (ten men, six women) patients with genetically confirmed Anderson-Fabry disease underwent cardiac MRI before starting enzyme replacement therapy (baseline study) and after 48 months of treatment with agalsidase beta at the dose of 1 mg/kg (follow-up study). Results: After 48 months of treatment, a significant reduction in LV mass and wall thickness was observed: 187±59 g vs. 149±44 g, and 16±3 mm vs. 13±3 mm, respectively. A significant reduction in T2 relaxation time was noted at the level of the interventricular septum (81±3 ms vs. 67±7 ms), at the apical level (80±8 ms vs. 63±6 ms) and at the level of the lateral wall (82±8 ms vs. 63±10 ms) (p0.05) (mean bias 1.0); however, an improvement was noted in the New York Heart Association (NYHA) class of the majority of patients (12/16) (p
Purpose: Anderson-Fabry disease is a multisystemic disorder of lipid metabolism secondary to X-chromosome alterations and is frequently associated with cardiac manifestations such as left ventricular (LV) hypertrophy, gradually leading to an alteration in cardiac performance. The purpose of this study was to monitor, using magnetic resonance imaging (MRI), any changes produced by enzyme replacement therapy with agalsidase beta at the cardiac level in patients with Anderson-Fabry disease. Materials and methods: Sixteen (ten men, six women) patients with genetically confirmed Anderson-Fabry disease underwent cardiac MRI before starting enzyme replacement therapy (baseline study) and after 48 months of treatment with agalsidase beta at the dose of 1 mg/kg (follow-up study). Results: After 48 months of treatment, a significant reduction in LV mass and wall thickness was observed: 187±59 g vs. 149±44 g, and 16±3 mm vs. 13±3 mm, respectively. A significant reduction in T2 relaxation time was noted at the level of the interventricular septum (81±3 ms vs. 67±7 ms), at the apical level (80±8 ms vs. 63±6 ms) and at the level of the lateral wall (82±8 ms vs. 63±10 ms) (p0.05) (mean bias 1.0); however, an improvement was noted in the New York Heart Association (NYHA) class of the majority of patients (12/16) (p
Role of cardiac MRI in evaluating patients with Anderson-Fabry disease: Assessing cardiac effects of long-term enzyme replacement therapy
No results. |
Role of cardiac MRI in evaluating patients with Anderson-Fabry disease: Assessing cardiac effects of long-term enzyme replacement therapy
Other filter: ([btitle,keywords] "Anderson-Fabry Disea ...
Imbriaco M, Pellegrino T, Piscopo V, Petretta M, Ponsiglione A, Nappi C, Puglia M, Dell'Aversana S, Riccio E, Spinelli L, Pisani A, Cuocolo A
* Cardiac sympathetic neuronal damage precedes myocardial fibrosis in patients with Anderson-Fabry disease (622 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 1619-7070print), 2017 Jul 22; N/D: N/D-N/D.
Impact Factor: 7.704
View Export to BibTeX Export to EndNote
Spinelli L, Pellegrino T, Pisani A, Giudice CA, Riccio E, Imbriaco M, Salvatore M, Trimarco B, Cuocolo A
* Relationship between left ventricular diastolic function and myocardial sympathetic denervation measured by (123)I-meta-iodobenzylguanidine imaging in Anderson-Fabry disease (570 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 1619-7070print), 2016 Apr; 43(4): 729-739.
Impact Factor: 7.277
View Export to BibTeX Export to EndNote
Nappi C, Altiero M, Imbriaco M, Nicolai E, Giudice CA, Aiello M, Diomiaiuti CT, Pisani A, Spinelli L, Cuocolo A
* First experience of simultaneous PET/MRI for the early detection of cardiac involvement in patients with Anderson-Fabry disease (974 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 1619-7070print), 2015; 42(7): 1025-1031.
Impact Factor: 5.537
View Export to BibTeX Export to EndNote
Parenti G, Fecarotta S, la Marca G, Rossi B, Ascione S, Donati MA, Morandi LO, Ravaglia S, Pichiecchio A, Ombrone D, Sacchini M, Pasanisi MB, De Filippi P, Danesino C, Della Casa R, Romano A, Mollica C, Rosa M, Agovino T, Nusco E, Porto C, Andria G
* A Chaperone Enhances Blood Alpha-Glucosidase Activity In Pompe Disease Patients Treated With Enzyme Replacement Therapy (465 views)
Molecular Therapy, 2014 Nov; 22(11): 2004-2012.
Impact Factor: 6.425
View Export to BibTeX Export to EndNote
Andreotti G, Citro V, Correra A, Cubellis MV
* A thermodynamic assay to test pharmacological chaperones for Fabry disease (1231 views)
Bba-Gen Subjects (ISSN: 0925-4439, 0006-3002, 1570-9639), 2014 Mar; 1840(3): 1214-1224.
Impact Factor: 4.882
View Export to BibTeX Export to EndNote
Cammisa M, Correra A, Andreotti G, Cubellis MV
* Fabry_CEP: a tool to identify Fabry mutations responsive to pharmacological chaperones (846 views)
Orphanet Journal Of Rare Diseases (ISSN: 1750-1172), 2013 Jul 24; 8: 111-111.
Impact Factor: 3.958
View Export to BibTeX Export to EndNote
Palma G, Greco D, Innocenti S, Alfano B
* Method Of Generating 2d Or 3d Maps Of Mri T1 And T2 Relaxation Times (469 views) (PDF 264 views)
Patentsofficial Gazette Of The United States Patent And Trademark Office, 2012 Sep 05; 20120223710: 18-18.
Impact Factor: 0
View Export to BibTeX Export to EndNote
Andreotti G, Citro V, De Crescenzo A, Orlando P, Cammisa M, Correra A, Cubellis MV
* Therapy of Fabry disease with pharmacological chaperones: from in silico predictions to in vitro tests (1965 views)
Orphanet Journal Of Rare Diseases (ISSN: 1750-1172), 2011 Oct 17; 6: 66-66.
Impact Factor: 5.074
View Export to BibTeX Export to EndNote
Andreotti G, Guarracino MR, Cammisa M, Correra A, Cubellis MV
* Prediction of the responsiveness to pharmacological chaperones: lysosomal human alpha-galactosidase, a case of study (840 views)
Orphanet Journal Of Rare Diseases (ISSN: 1750-1172), 2010 Dec 8; 5: 36-36.
Impact Factor: 5.933
View Export to BibTeX Export to EndNote
Imbriaco M, Messalli G, Avitabile G, Cuocolo A, Maurea S, Soscia F, Pisani A
* Cardiac magnetic resonance imaging illustrating Anderson-Fabry disease progression (605 views)
Br J Radiol (ISSN: 0007-1285, 1748-880xelectronic, 0007-1285linking), 2010 Dec; 83(996): e249-e249.
Impact Factor: 2.062
View Export to BibTeX Export to EndNote
Imbriaco M, Pisani A, Spinelli L, Cuocolo A, Messalli G, Capuano E, Marmo M, Liuzzi R, Visciano B, Cianciaruso B, Salvatore M
* Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study (928 views)
Heart (ISSN: 1355-6037, 1468-201x), 2009 Jul; 95(13): 1103-1107.
Impact Factor: 5.385
View Export to BibTeX Export to EndNote
Imbriaco M, Spinelli L, Cuocolo A, Maurea S, Sica G, Quarantelli M, Pisani A, Liuzzi R, Cianciaruso B, Sabbatini M, Salvatore M
* MRI characterization of myocardial tissue in patients with Fabry's disease (1137 views)
Ajr Am J Roentgenol (ISSN: 1546-3141, 0361-803x, 1546-3141electronic), 2007 Mar; 188(3): 850-853.
Impact Factor: 2.47
View Export to BibTeX Export to EndNote
* Cardiac sympathetic neuronal damage precedes myocardial fibrosis in patients with Anderson-Fabry disease (622 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 1619-7070print), 2017 Jul 22; N/D: N/D-N/D.
Impact Factor: 7.704
View Export to BibTeX Export to EndNote
Spinelli L, Pellegrino T, Pisani A, Giudice CA, Riccio E, Imbriaco M, Salvatore M, Trimarco B, Cuocolo A
* Relationship between left ventricular diastolic function and myocardial sympathetic denervation measured by (123)I-meta-iodobenzylguanidine imaging in Anderson-Fabry disease (570 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 1619-7070print), 2016 Apr; 43(4): 729-739.
Impact Factor: 7.277
View Export to BibTeX Export to EndNote
Nappi C, Altiero M, Imbriaco M, Nicolai E, Giudice CA, Aiello M, Diomiaiuti CT, Pisani A, Spinelli L, Cuocolo A
* First experience of simultaneous PET/MRI for the early detection of cardiac involvement in patients with Anderson-Fabry disease (974 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 1619-7070print), 2015; 42(7): 1025-1031.
Impact Factor: 5.537
View Export to BibTeX Export to EndNote
Parenti G, Fecarotta S, la Marca G, Rossi B, Ascione S, Donati MA, Morandi LO, Ravaglia S, Pichiecchio A, Ombrone D, Sacchini M, Pasanisi MB, De Filippi P, Danesino C, Della Casa R, Romano A, Mollica C, Rosa M, Agovino T, Nusco E, Porto C, Andria G
* A Chaperone Enhances Blood Alpha-Glucosidase Activity In Pompe Disease Patients Treated With Enzyme Replacement Therapy (465 views)
Molecular Therapy, 2014 Nov; 22(11): 2004-2012.
Impact Factor: 6.425
View Export to BibTeX Export to EndNote
Andreotti G, Citro V, Correra A, Cubellis MV
* A thermodynamic assay to test pharmacological chaperones for Fabry disease (1231 views)
Bba-Gen Subjects (ISSN: 0925-4439, 0006-3002, 1570-9639), 2014 Mar; 1840(3): 1214-1224.
Impact Factor: 4.882
View Export to BibTeX Export to EndNote
Cammisa M, Correra A, Andreotti G, Cubellis MV
* Fabry_CEP: a tool to identify Fabry mutations responsive to pharmacological chaperones (846 views)
Orphanet Journal Of Rare Diseases (ISSN: 1750-1172), 2013 Jul 24; 8: 111-111.
Impact Factor: 3.958
View Export to BibTeX Export to EndNote
Palma G, Greco D, Innocenti S, Alfano B
* Method Of Generating 2d Or 3d Maps Of Mri T1 And T2 Relaxation Times (469 views) (PDF 264 views)
Patentsofficial Gazette Of The United States Patent And Trademark Office, 2012 Sep 05; 20120223710: 18-18.
Impact Factor: 0
View Export to BibTeX Export to EndNote
Andreotti G, Citro V, De Crescenzo A, Orlando P, Cammisa M, Correra A, Cubellis MV
* Therapy of Fabry disease with pharmacological chaperones: from in silico predictions to in vitro tests (1965 views)
Orphanet Journal Of Rare Diseases (ISSN: 1750-1172), 2011 Oct 17; 6: 66-66.
Impact Factor: 5.074
View Export to BibTeX Export to EndNote
Andreotti G, Guarracino MR, Cammisa M, Correra A, Cubellis MV
* Prediction of the responsiveness to pharmacological chaperones: lysosomal human alpha-galactosidase, a case of study (840 views)
Orphanet Journal Of Rare Diseases (ISSN: 1750-1172), 2010 Dec 8; 5: 36-36.
Impact Factor: 5.933
View Export to BibTeX Export to EndNote
Imbriaco M, Messalli G, Avitabile G, Cuocolo A, Maurea S, Soscia F, Pisani A
* Cardiac magnetic resonance imaging illustrating Anderson-Fabry disease progression (605 views)
Br J Radiol (ISSN: 0007-1285, 1748-880xelectronic, 0007-1285linking), 2010 Dec; 83(996): e249-e249.
Impact Factor: 2.062
View Export to BibTeX Export to EndNote
Imbriaco M, Pisani A, Spinelli L, Cuocolo A, Messalli G, Capuano E, Marmo M, Liuzzi R, Visciano B, Cianciaruso B, Salvatore M
* Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study (928 views)
Heart (ISSN: 1355-6037, 1468-201x), 2009 Jul; 95(13): 1103-1107.
Impact Factor: 5.385
View Export to BibTeX Export to EndNote
Imbriaco M, Spinelli L, Cuocolo A, Maurea S, Sica G, Quarantelli M, Pisani A, Liuzzi R, Cianciaruso B, Sabbatini M, Salvatore M
* MRI characterization of myocardial tissue in patients with Fabry's disease (1137 views)
Ajr Am J Roentgenol (ISSN: 1546-3141, 0361-803x, 1546-3141electronic), 2007 Mar; 188(3): 850-853.
Impact Factor: 2.47
View Export to BibTeX Export to EndNote
12 Records (7 excluding Abstracts).
Total impact factor: 56.707 (39.68 excluding Abstracts).
Total 5 year impact factor: 56.464 (36.801 excluding Abstracts).
Total impact factor: 56.707 (39.68 excluding Abstracts).
Total 5 year impact factor: 56.464 (36.801 excluding Abstracts).
580 views. Last view on Wednesday 30 April 2025, 6:16:51
ibb.cnr.it
